Hutchison China Meditech Limited Total Voting Rights (9078S)
29 Juin 2018 - 8:02AM
UK Regulatory
TIDMHCM
RNS Number : 9078S
Hutchison China Meditech Limited
29 June 2018
Total Voting Rights
London: Friday, June 29, 2018: Hutchison China MediTech Limited
("Chi-Med") (AIM/Nasdaq: HCM) hereby notifies the market that as at
June 29, 2018, the issued share capital of Chi-Med consisted of
66,532,683 ordinary shares of US$1.00 each, with each share
carrying one right to vote and with no shares held in treasury.
The above figure of 66,532,683 may be used by shareholders as
the denominator for the calculations by which they could determine
if they are required to notify their interest in, or a change to
their interest in, Chi-Med under the Financial Conduct Authority's
Disclosure Rules and Transparency Rules.
For illustrative purposes only, the 66,532,683 ordinary shares
would be equivalent to 66,532,683 CREST depositary interests (each
equating to one ordinary share) which are traded on AIM or, if the
CREST depositary interests were converted in their entirety,
equivalent to 133,065,366 American depositary shares (each equating
to one-half of one ordinary share) which are traded on Nasdaq.
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which
researches, develops, manufactures and sells pharmaceuticals and
healthcare products. Its Innovation Platform, Hutchison MediPharma
Limited, focuses on discovering and developing innovative
therapeutics in oncology and autoimmune diseases for the global
market. Its Commercial Platform manufactures, markets, and
distributes prescription drugs and consumer health products in
China.
Chi-Med is majority owned by the multinational conglomerate CK
Hutchison Holdings Limited (SEHK: 1). For more information, please
visit: www.chi-med.com.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President,
Corporate Finance & Development +852 2121 8200
U.K. & International Media Enquiries
Anthony Carlisle, +44 7973 611 888 (Mobile)
Citigate Dewe Rogerson anthony.carlisle@cdrconsultancy.co.uk
U.S. Based Media Enquiries
Brad Miles, Solebury Trout +1 (917) 570 7340 (Mobile)
bmiles@troutgroup.com
Susan Duffy, Solebury Trout +1 (917) 499 8887 (Mobile)
sduffy@troutgroup.com
Investor Relations
Xuan Yang, Solebury Trout +1 (415) 971 9412 (Mobile)
xyang@troutgroup.com
David Dible, +44 7967 566 919 (Mobile)
Citigate Dewe Rogerson david.dible@citigatedewerogerson.com
Panmure Gordon (UK) Limited
Richard Gray / Andrew Potts +44 (20) 7886 2500
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
TVREANKPALFPEEF
(END) Dow Jones Newswires
June 29, 2018 02:02 ET (06:02 GMT)
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024